Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Braden Brklacich

Podiatrist, Foot & Ankle Surgery Riverton, UT Doctor of Podiatric Medicine

NPI 1609397207 CMS profile 5699090

12523 S Creek Meadow Rd Ste 105, Ste 303, Riverton, UT 84065

Open in the dashboard

General payments

$6,989

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Braden Brklacich of Riverton, UT is reported in the CMS Open Payments database as having received $6,989 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $207 4
2023 General $1,254 15
2022 General $2,045 23
2021 General $1,335 4
2020 General $79 4
2019 General $2,068 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Braden Brklacich
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Braden Brklacich were reported at $207. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Braden Brklacich Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $2,068 $389 $118–$1,406 $163
2020 $79 $191 $62–$691 $114
2021 $1,335 $329 $104–$1,341 $132
2022 $2,045 $419 $125–$1,611 $149
2023 $1,254 $377 $128–$1,164 $160
2024 $0 $394 $134–$1,168 $164
2025 $207 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,085 22 payments
  2. Active Medical, LLC $2,068 3 payments
  3. Paragon 28, Inc. $1,263 3 payments
  4. Anika Therapeutics, Inc. $625 3 payments
  5. Organogenesis Inc. $248 10 payments
  6. Triad Life Sciences Inc. $191 1 payment
  7. Abbott Laboratories $152 1 payment
  8. Fusion Orthopedics, LLC. $136 1 payment
  9. Bone Support Inc. $73 1 payment
  10. Kowa Pharmaceuticals America, Inc. $42 3 payments
  11. Other $105 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,548 8 payments
  2. Food and Beverage $2,373 42 payments
  3. Education $2,068 3 payments
Products named General payments · program years 2019–2025
  1. PROSTEP $1,683 12 payments
  2. Product Portfolio $1,263 3 payments
  3. X-Twist $591 1 payment
  4. Drawtight $591 1 payment
  5. Tactoset $591 1 payment
  6. Puraply $248 10 payments
  7. N/A $236 4 payments
  8. INNOVAMATRIX AC $191 1 payment
  9. PROCLAIM $152 1 payment
  10. CERAMENTBONE VOID FILLER $73 1 payment
  11. Other $337 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

171

Median for Podiatry: 160

Drug cost

$1,685

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 25 $534
Terbinafine Hcl Generic 25 $488
Prednisone Generic 54 $270
Gabapentin Generic 19 $213
Cephalexin Generic 16 $105
Meloxicam Generic 32 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$793,266

Of which drugs: $252,403

Medicare patients

367

Average age 79

Services billed

9,040

194 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 43%
Diabetes 39%
Ischemic heart disease 31%
Atrial fibrillation 25%
Depression 24%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 68 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record